Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc.
21925 W. Field Parkway
Suite 235
Deer Park, IL 60010-7278
United States
847 787 7361
https://www.etonpharma.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 30
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Sean E. Brynjelsen | President, CEO & Director | 939.42k | N/D | 1972 |
| Mr. James R. Gruber CPA | CFO, Treasurer & Secretary | 554.44k | N/D | 1972 |
| Mr. David C. Krempa | Chief Business Officer | 547.86k | N/D | 1989 |
| Ms. Ingrid Hoos | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Mr. Kevin Guthrie | Executive VP of Commercial Operations | N/D | N/D | N/D |
Descripción
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Gestión corporativa
La calificación ISS Governance QuickScore de Eton Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
